Inovio
Pharmaceuticals Inc. (Nasdaq: INO) narrowed fourth quarter losses more than
expected to 12 cents per share from 30 cents per share in the year ago period and announced that it received a five year $16 million
Integrated Preclinical/Clinical AIDS Vaccine Development Program grant. The stock price soared $1.43 to $8.47.
Inovio narrows losses, receives $16 million grant
March 16, 2015 at 14:24 PM EDT